Experimental Data Snapshot
Starting Model:experimental
View more details
wwPDB Validation  3D Report Full Report
(2011) PLoS One 6: e20033-e20033
Increased spread of HIV-1 and rapid emergence of drug resistance warrants development of novel antiviral strategies. Nef, a critical viral pathogenicity factor that interacts with host cell factors but lacks enzymatic activity, is not targeted by current antiviral measures. Here we inhibit Nef function by simultaneously blocking several highly conserved protein interaction surfaces. This strategy, referred to as "wrapping Nef", is based on structure-function analyses that led to the identification of four target sites: (i) SH3 domain interaction, (ii) interference with protein transport processes, (iii) CD4 binding and (iv) targeting to lipid membranes. Screening combinations of Nef-interacting domains, we developed a series of small Nef interacting proteins (NIs) composed of an SH3 domain optimized for binding to Nef, fused to a sequence motif of the CD4 cytoplasmic tail and combined with a prenylation signal for membrane association. NIs bind to Nef in the low nM affinity range, associate with Nef in human cells and specifically interfere with key biological activities of Nef. Structure determination of the Nef-inhibitor complex reveals the molecular basis for binding specificity. These results establish Nef-NI interfaces as promising leads for the development of potent Nef inhibitors.
 Explore in 3D: Structure |Sequence Annotations |Electron Density |Validation Report
Biological assembly 1 assigned by authors and generated by PISA (software)
 Explore in 3D: Structure |Sequence Annotations |Electron Density |Validation Report
Biological assembly 2 assigned by authors and generated by PISA (software)
Macromolecule Content 
Entity ID: 1 | |||||
|---|---|---|---|---|---|
| Molecule | Chains | Sequence Length | Organism | Details | Image |
| Protein Nef | 166 | HIV-1 M:B_ARV2/SF2 | Mutation(s): 4  Gene Names: HIV-1 Nef, nef | ![]() | |
UniProt | |||||
Find proteins for P03407 (Human immunodeficiency virus type 1 group M subtype B (isolate ARV2/SF2)) Explore P03407  Go to UniProtKB:  P03407 | |||||
Entity Groups  | |||||
| Sequence Clusters | 30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity | ||||
| UniProt Group | P03407 | ||||
Sequence AnnotationsExpand | |||||
| |||||
Entity ID: 2 | |||||
|---|---|---|---|---|---|
| Molecule | Chains | Sequence Length | Organism | Details | Image |
| Tyrosine-protein kinase HCK | 61 | Homo sapiens | Mutation(s): 6  Gene Names: HCK EC: 2.7.10.2 | ![]() | |
UniProt & NIH Common Fund Data Resources | |||||
Find proteins for P08631 (Homo sapiens) Explore P08631  Go to UniProtKB:  P08631 | |||||
PHAROS:  P08631 GTEx:  ENSG00000101336  | |||||
Entity Groups  | |||||
| Sequence Clusters | 30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity | ||||
| UniProt Group | P08631 | ||||
Sequence AnnotationsExpand | |||||
| |||||
| Length ( Å ) | Angle ( ˚ ) |
|---|---|
| a = 65.692 | α = 90 |
| b = 65.692 | β = 90 |
| c = 279.068 | γ = 90 |
| Software Name | Purpose |
|---|---|
| ADSC | data collection |
| REFMAC | refinement |
| XDS | data reduction |
| XSCALE | data scaling |
| REFMAC | phasing |
RCSB PDB Core Operations are funded by theU.S. National Science Foundation (DBI-2321666), theUS Department of Energy (DE-SC0019749), and theNational Cancer Institute,National Institute of Allergy and Infectious Diseases, andNational Institute of General Medical Sciences of theNational Institutes of Health under grant R01GM157729. RCSB PDB uses resources of the National Energy Research Scientific Computing Center (NERSC), a Department of Energy User Facility.